Cargando…

Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial

AIMS: The impact of exercise training on the right heart and pulmonary circulation has not yet been invasively assessed in patients with pulmonary hypertension (PH) and right heart failure. This prospective randomized controlled study investigates the effects of exercise training on peak VO(2)/kg, h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ehlken, Nicola, Lichtblau, Mona, Klose, Hans, Weidenhammer, Johannes, Fischer, Christine, Nechwatal, Robert, Uiker, Sören, Halank, Michael, Olsson, Karen, Seeger, Werner, Gall, Henning, Rosenkranz, Stephan, Wilkens, Heinrike, Mertens, Dirk, Seyfarth, Hans-Jürgen, Opitz, Christian, Ulrich, Silvia, Egenlauf, Benjamin, Grünig, Ekkehard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692286/ https://www.ncbi.nlm.nih.gov/pubmed/26231884 http://dx.doi.org/10.1093/eurheartj/ehv337

Ejemplares similares

Exercise Training Improves Exercise Capacity and Quality of Life in Patients with Inoperable or Residual Chronic Thromboembolic Pulmonary Hypertension
por: Nagel, Christian, et al.
Publicado: (2012)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Harzheim, Dominik, et al.
Publicado: (2013)

Exercise training in pulmonary arterial hypertension associated with connective tissue diseases
por: Grünig, Ekkehard, et al.
Publicado: (2012)

Identification of a New Intronic BMPR2-Mutation and Early Diagnosis of Heritable Pulmonary Arterial Hypertension in a Large Family with Mean Clinical Follow-Up of 12 Years
por: Hinderhofer, Katrin, et al.
Publicado: (2014)

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?
por: Theobald, Vivienne, et al.
Publicado: (2022)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Mutation in BMPR2 Promoter: A ‘Second Hit’ for Manifestation of Pulmonary Arterial Hypertension?
por: Viales, Rebecca Rodríguez, et al.
Publicado: (2015)

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension
por: Eichstaedt, Christina A., et al.
Publicado: (2022)

Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis
por: Schmidt, Kai-Helge, et al.
Publicado: (2023)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

Optical coherence tomography improves the results of balloon pulmonary angioplasty in inoperable chronic thrombo-embolic pulmonary hypertension
por: Araszkiewicz, Aleksander, et al.
Publicado: (2017)

Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients?
por: Theobald, Vivienne, et al.
Publicado: (2023)

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
por: Richter, Manuel J., et al.
Publicado: (2020)

Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry
por: Hoeper, Marius M., et al.
Publicado: (2022)

Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients
por: Lerche, Marianne, et al.
Publicado: (2019)

Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension—A Genetic Study
por: Eichstaedt, Christina A., et al.
Publicado: (2020)

Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study( )
por: Valerio, Luca, et al.
Publicado: (2022)

Stress Doppler echocardiography for early detection of systemic sclerosis-associated pulmonary arterial hypertension
por: Nagel, Christian, et al.
Publicado: (2015)

COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
por: Hoeper, Marius M., et al.
Publicado: (2022)

Monotherapy in patients with pulmonary arterial hypertension at four German PH centres
por: Stubbe, Beate, et al.
Publicado: (2021)

Diagnostic accuracy of automated 3D volumetry of cardiac chambers by CT pulmonary angiography for identification of pulmonary hypertension due to left heart disease
por: Melzig, Claudius, et al.
Publicado: (2022)

Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis
por: Hoeper, Marius M, et al.
Publicado: (2022)

Imaging the heart in pulmonary hypertension: an update
por: Grünig, Ekkehard, et al.
Publicado: (2015)

Fibrinogen plasma concentration is an independent marker of haemodynamic impairment in chronic thromboembolic pulmonary hypertension
por: Hennigs, Jan K., et al.
Publicado: (2014)

Right Heart Size and Right Ventricular Reserve in Pulmonary Hypertension: Impact on Management and Prognosis
por: Grünig, Ekkehard, et al.
Publicado: (2020)

Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations
por: Pfarr, Nicole, et al.
Publicado: (2011)

Pulmonary arterial wedge pressure increase during exercise in patients diagnosed with pulmonary arterial or chronic thromboembolic pulmonary hypertension
por: Müller, Julian, et al.
Publicado: (2023)

Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres
por: Wissmüller, Max, et al.
Publicado: (2022)

Undersized ballooning strategy for chronic thrombo-embolic pulmonary hypertension
por: Chen, Yaling, et al.
Publicado: (2022)

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri(®)): a prospective, 6-months, open label, observational, non-interventional study
por: Degering, Julia, et al.
Publicado: (2023)

Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy
por: Knudsen, Lars, et al.
Publicado: (2011)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Impact of SARS-CoV-2 pandemic on pulmonary hypertension out-patient clinics in Germany: a multi-centre study
por: Yogeswaran, Athiththan, et al.
Publicado: (2020)

The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)
por: Cima, Katharina, et al.
Publicado: (2012)

N-Terminal Pro-Brain Natriuretic Peptide Is a Useful Prognostic Marker in Patients with Pre-Capillary Pulmonary Hypertension and Renal Insufficiency
por: Harbaum, Lars, et al.
Publicado: (2014)

Progress in the treatment of acute pulmonary embolism and chronic thrombo-embolic pulmonary hypertension/disease
por: Palazzini, Massimiliano, et al.
Publicado: (2023)

Hemodynamic and genetic analysis in children with idiopathic, heritable, and congenital heart disease associated pulmonary arterial hypertension
por: Pfarr, Nicole, et al.
Publicado: (2013)

Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat
por: Smith, Zachary R, et al.
Publicado: (2016)

Acute effects of exercise on the inflammatory state in patients with idiopathic pulmonary arterial hypertension
por: Harbaum, Lars, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bg3o0vqduspbg2ajsr8rd1a5ah